Quote:

---

While these drugs (GLP-1 agonists) do have their benefits, among the negatives it's the gastroparesis which concerns me the most...Any idea whether it resolves with discontinuation of the drug?

---

In almost all cases discontinuation reverses the effects. More problematic is inflammation of the pancreas, kidneys and heart. Once inflammation starts it can go into a feedback loop that results in low level chronic inflammation after drug discontinuation. The problem with GLP-1 agonists is that they boost GLP-1 levels very high causing an imbalance, that leads to rapid weight loss but induces the side effects. That rapid weight loss is why GLP-1 agonists combined with leronlimab might reduce liver fat faster than leronlimab alone but would almost certainly increase adverse events if not serious adverse events. I think leronlimab's slower effect on reversal of liver fat via a lower increase of GLP-1, T-3/T-4 regulation (like resmetirom) and preferential expression of brown fat (good) vs. white fat (bad) would be better than added AEs and SAEs.